MOUSE MODELS OF GASTROINTESTINAL CANCER

在过去的十年里，辛辛那提大学医学院对基因功能的研究做出了重大承诺。我们的转基因和敲除小鼠核心设施已经生产了600多个转基因小鼠品系和100多个敲除小鼠品系。 1996年，建立了一个基因靶向核心设施，仅在1998年就靶向了27个不同的基因。 此外，医学院在发展比较病理学和小鼠生理学核心设施方面处于最前沿，这些设施在数十种转基因和敲除菌株的表征中发挥了重要作用，这些菌株的表型从植入前和先天性缺陷到心血管疾病再到癌症。 最近，对癌症的机构重点已经导致招聘了许多临床和基础科学研究教师与杰出的研究成就，特别是在癌症遗传学领域。 随着小鼠遗传学的机构基础设施已经到位，参与人类癌症小鼠模型联盟将大大扩大我们在癌症生物学领域的基因发现和基因功能研究潜力。 所有这些，再加上对功能基因组学的新关注，应该使我们能够充分利用我们的人类癌症小鼠模型，并为小鼠模型的未来做出贡献。 我们已经提出了一个有针对性的计划，以表征，操作和开发新的胃肠道肿瘤小鼠模型。 通过参与该联盟，我们希望贡献我们的经验、模型和新的想法，以便将下一代功能基因组学技术、药物和治疗性蛋白质发现的进展以及药物基因组学应用于胃肠道癌症的诊断和治疗。

Over the last decade, The University of Cincinnati College of Medicine has made a major commitment to studies of gene function. Our Transgenic and Knockout Mouse Core Facilities have produced over 600 transgenic mouse strains and over 100 knockout mouse strains. In 1996, a Gene Targeting Core Facility was established which in 1998 alone targeted 27 different genes. In addition, the College of Medicine was at the very forefront in developing Comparative Pathology and Mouse Physiology Core Facilities that have played essential roles in the characterization of dozens of transgenic and knockout strains with phenotypes ranging from preimplantation and congenital defects to cardiovascular disorders to cancer. More recently, an institutional focus on cancer has resulted in the recruitment of numerous clinical and basic science research faculty with outstanding research accomplishments, especially in the area of cancer genetics. With the institutional infrastructure for mouse genetics already in place, participation in the Mouse Models of Human Cancers Consortium will expand considerably our gene discovery and gene function research potential in the area of cancer biology. All of this, coupled with new focus on functional genomics, should give us the ability to make the most of our mouse models of human cancer and to contribute to the future of mouse modeling. We have proposed a focused plan to characterize, manipulate and develop new mouse models of gastrointestinal cancer. Through our participation in the Consortium, we hope to contribute our experience, models and new ideas in order to apply the next generation of functional genomics technologies, advances in drug and therapeutic protein discovery, and pharmacogenomics to the diagnosis and treatment of gastrointestinal cancer.